This paper (behind a paywall) shows the ongoing biological variation in thyroid hormone parameters in healthy subjects. It shows that such variations are much less for FT3 and FT4 as compared with TSH variation. This study gives the lie to any GP's or endocrinologists that, for example, FT3 levels vary so much in patients (except of course when direct T3 dosing is done). It implies that T4-only treatment will not be accompanied by large swings in FT3.
European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum thyroid biomarkers based on weekly samplings from 91 healthy participants
February 2021Clinical Chemistry and Laboratory Medicine
DOI: 10.1515/cclm-2020-1885
Project: Biological Variation : new estimates from EuBIVAS , a project drawn by EFLM WG on BV
Michela Bottani, Aasne K Aarsand, Giuseppe Banfi, Anna Carobene
Abstract
Objectives: Thyroid biomarkers are fundamental for the diagnosis of thyroid disorders and for the monitoring and treatment of patients with these diseases. The knowledge of biological variation (BV) is important to define analytical performance specifications (APS) and reference change values (RCV). The aim of this study was to deliver BV estimates for thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroglobulin (TG), and calcitonin (CT).
Methods: Analyses were performed on serum samples obtained from the European Biological Variation Study population (91 healthy individuals from six European laboratories; 21-69 years) on the Roche Cobas e801 at the San Raffaele Hospital (Milan, Italy). All samples from each individual were evaluated in duplicate within a single run. The BV estimates with 95% CIs were obtained by CV-ANOVA, after analysis of variance homogeneity and outliers.
Results: The within-subject (CV I ) BV estimates were for TSH 17.7%, FT3 5.0%, FT4 4.8%, TG 10.3, and CT 13.0%, all significantly lower than those reported in the literature. No significant differences were observed for BV estimates between men and women. Conclusions: The availability of updated, in the case of CT not previously published, BV estimates for thyroid markers based on the large scale EuBIVAS study allows for refined APS and associated RCV applicable in the diagnosis and management of thyroid and related diseases.